Gerard Brophy - 23 Feb 2023 Form 4 Insider Report for Avantor, Inc. (AVTR)

Role
EVP, Biopharma Production
Signature
/s/ Scott Baker, as Attorney-in-Fact
Issuer symbol
AVTR
Transactions as of
23 Feb 2023
Net transactions value
-$96,774
Form type
4
Filing time
27 Feb 2023, 19:10:08 UTC
Previous filing
22 Feb 2023
Next filing
01 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTR Common Stock Tax liability $46,549 -1,893 -1.9% $24.59 97,420 23 Feb 2023 Direct F1
transaction AVTR Common Stock Award $0 +20,308 +21% $0.000000 117,728 24 Feb 2023 Direct F2
transaction AVTR Common Stock Tax liability $50,225 -2,040 -1.7% $24.62 115,688 25 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTR Stock Options (Right to Buy) Award $0 +49,215 $0.000000 49,215 24 Feb 2023 Common Stock 49,215 $24.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
F2 Reflects a grant of restricted stock units that vest in four equal annual installments beginning on February 24, 2024.
F3 Reflects a grant of stock options that vest in four equal annual installments beginning on February 24, 2024.